TNFRSF10B and neoplasm: In the current work, we generated the bispecific fusion protein DR5-B-iRGD based on the DR5-selective TRAIL variant DR5-B [22], which was aimed specifically to target two distinct receptors, DR5 and integrin αvβ3, which are both associated with tumor development.